BETAAccess all features while we're in beta! Some features may become paid later.Got feedback? Reach us 👉

Loading TVTX charts…

Search ticker or company⌘K

TVTX

01Multicharts 02Comparables 03Price target

May we use analytics cookies to see how vpside is used, including anonymous session recordings? Accepting also loads the price chart, which sets its own cookies. Essential cookies are always on. Privacy

TVTX · Travere Therapeutics, Inc. fundamentals · vpside

vpside

⌘K

TVTXMarket cap $4.7B/Last filing 10-Q, Q2 FY26 · 4 Aug 2026/TVTXMarket cap $4.7B/Last filing 10-Q, Q2 FY26 · 4 Aug 2026/TVTXMarket cap $4.7B/Last filing 10-Q, Q2 FY26 · 4 Aug 2026/TVTXMarket cap $4.7B/Last filing 10-Q, Q2 FY26 · 4 Aug 2026/

Filings synced 13:22 · Prices: prior close 30 Oct

TVTX

Travere Therapeutics, Inc.

Nasdaq · Pharmaceutical preparations (SIC 2834) · FY ends 31 Dec

01Multicharts 02Comparables 03Price target

Add a metric37 metrics

Revenue, quarterly

$170M+48.2% year on year

$200M$100M$0−$100M

vpside.com

Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26

Company filings · 10-Q filed 4 Aug 2026 · Q4 = FY − 9Mvpside.com

Gross margin, trailing twelve months

98.6%+1.7 pp year on year

100%95%90%85%

vpside.com

Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26

Company filings · 10-Q filed 4 Aug 2026 · TTM = last four quartersvpside.com

Cash and cash equivalents, quarter-end

$118M+56.7% year on year

$300M$200M$100M$0

vpside.com

Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26

Company filings · 10-Q filed 4 Aug 2026 · balance sheet, period-endvpside.com

Free cash flow, trailing twelve months

−$272M

$200M$0−$200M−$400M

vpside.com

Q4 ’19Q1 ’21Q2 ’22Q2 ’23Q3 ’24

Company filings · 10-Q filed 30 Oct 2025 · TTM = last four quartersvpside.com

Chart 05 is empty

Chart 06 is empty

Fundamentals: company filings · Q4 = full year − nine months · TTM = last four quarters